Guided self-help for anxiety among Huntington’s disease gene expansion carriers compared to treatment as usual: a randomised controlled feasibility trial (GUIDE-HD)

eicestershire Partnership NHS Trust0 个研究点目标入组 36 人开始时间: 2022年9月28日最近更新: 2023年10月16日

试验速览

2023 Protocol article in https://pubmed.ncbi.nlm.nih.gov/37700320/ (added 14/09/2023)

•Huntington's Disease Participants
•1. Confirmed genetic test for HD (CAG >=36)
•2. Diagnosed with clinical anxiety using Structured Clinical Interview for DSM-5 (SCID-5)
•3. Premanifest or manifest HD
•4. For those who are manifest HD, will be early-stage HD as defined as those with a United Huntington’s Disease Rating Scale (UHDRS) Total Functional Capacity (TFC) score of 9-13
•4. If taking a medication known to impact on anxiety, must be stabilised for 4 weeks
•5. Able to read/understand English
•6. Aged >=18 years
•7. Able and willing to give informed consent
•1. Aged >=18 years
•2. Had some involvement in the intervention
•3. Able to give informed consent

•HD Participants
•1. Current suicidal intent
•2. Significant cognitive or communication impairment as determined by MOCA and clinical psychologist opinion
•3. Unstable medical conditions
•4. Currently receiving another psychological intervention aimed at reducing anxiety
•5. Acute psychosis or other acute psychiatric presentation requiring intense/urgent input from mental health professionals

发起方

eicestershire Partnership NHS Trust